Related Experiment Video
Updated: Sep 27, 2025

Characterization of Functionally Associated miRNAs in Glioblastoma and their Engineering into Artificial Clusters for Gene Therapy
Published on: October 4, 2019
The mesoionic compound MI-D changes energy metabolism and induces apoptosis in T98G glioma cells
Marília Locatelli Corrêa-Ferreira1, Amanda do Rocio Andrade Pires1, Igor Resendes Barbosa2
1Department of Biochemistry and Molecular Biology, Federal University of Parana, Curitiba, Brazil.
Abstract:
The mesoionic compound 4-phenyl-5-(4-nitro-cinnamoyl)-1,3,4-thiadiazolium-2-phenylamine chloride (MI-D) impairs mitochondrial oxidative phosphorylation and has a significant antitumour effect against hepatocarcinoma and melanoma. This study evaluated the cytotoxic effect of MI-D on T98G glioblastoma cells and investigated whether the impairment of oxidative phosphorylation promoted by MI-D is relevant to its cytotoxic effect. The effects of MI-D on T98G cells cultured in high glucose Dulbecco's modified Eagle's medium (DMEM) HG (glycolysis-dependent) and galactose plus glutamine-supplemented Dulbecco's modified Eagle's medium (DMEM) GAL (oxidative phosphorylation-dependent) were compared. T98G cells grown in DMEM GAL medium exhibited higher respiration rates and citrate synthase activity and lower lactate levels, confirming the metabolic shift to oxidative phosphorylation in these cells. MI-D significantly decreased the cell viability in a dose-dependent manner in both media; however, T98G cells cultured in DMEM GAL medium were more susceptible. The mesoionic significantly inhibited mitochondrial oxidative phosphorylation of glioma cells in both media. At the same time, lactate levels were not altered, indicating an absence of compensatory glycolysis activation. Additionally, MI-D increased the citrate synthase activity of cells in both media, which in DMEM HG-cultivated cells was followed by citrate accumulation. Apoptosis dependent on caspase-3 mediated the toxicity of MI-D on T98G cells. The higher susceptibility of glioma cells cultured in DMEM GAL medium to MI-D indicates that the impairment of mitochondrial functions is involved in mesoionic cytotoxicity. The results of this study indicate the potential use of MI-D for glioblastoma treatment.
Insights
The mesoionic compound MI-D shows anti-cancer potential by impairing mitochondrial function in glioblastoma cells. This compound is more effective when cells rely on oxidative phosphorylation, suggesting a targeted therapeutic approach.
Area of Science:
- Biochemistry
- Cell Biology
- Pharmacology
Background:
- Mesoionic compounds, like MI-D, exhibit antitumor properties by affecting mitochondrial oxidative phosphorylation.
- Glioblastoma is an aggressive brain tumor with limited treatment options.
Purpose of the Study:
- To evaluate the cytotoxic effect of MI-D on T98G glioblastoma cells.
- To determine if MI-D's impairment of oxidative phosphorylation is linked to its cytotoxic activity.
Main Methods:
- Comparing MI-D's effects on T98G cells in high-glucose (glycolysis-dependent) and galactose-supplemented (oxidative phosphorylation-dependent) media.
- Assessing cell viability, mitochondrial respiration, citrate synthase activity, and lactate levels.
- Investigating the role of caspase-3 mediated apoptosis.
Main Results:
- MI-D decreased T98G cell viability in both media, with greater susceptibility in galactose-supplemented medium.
- MI-D inhibited mitochondrial oxidative phosphorylation and increased citrate synthase activity without compensatory glycolysis.
- Caspase-3 mediated apoptosis was identified as the mechanism of MI-D toxicity.
Conclusions:
- Impairment of mitochondrial function is crucial for MI-D's cytotoxic effects on glioblastoma cells.
- MI-D demonstrates potential as a therapeutic agent for glioblastoma treatment.
More Related Videos
09:17Characterization of the Effects of Migrastatic Inhibitors on 3D Tumor Spheroid Invasion by High-resolution Confocal Microscopy
Published on: September 16, 2019
06:54Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells
Published on: October 27, 2020